John F. Gerecitano - Concepedia

Author

John F. Gerecitano

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

J Gerecitano, J. F. Gerecitano, J. Gerecitano, J.F. Gerecitano, JOHN GERECITANO, John F Gerecitano, John F. Gerecitano, John Gerecitano

204

Publications

10.5K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Peter MacCallum Cancer Centre

About

John F. Gerecitano is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	32	4.2K
2	Health Sciences	11	11	1.3K
3	Engineering	1	1	23
4	Natural Sciences	1	1	293
5	Biomedical Engineering	1	1	12

John F. Gerecitano

Publications

10K

Citations

H-Index

Page 1

	Year	Citations
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia Andrew W. Roberts, Matthew S. Davids, John M. Pagel, New England Journal of Medicine	2015	1.8K
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wyndham H. Wilson, Ryan M. Young, Roland Schmitz, Nature Medicine Lymphoid NeoplasiaMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2015	1.1K
Requirement for Transcription Factor IRF-1 in NO Synthase Induction in Macrophages Ryutaro Kamijo, Hisashi Harada, T. Matsuyama, Science	1994	843
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman, The Lancet Oncology Hematological MalignancyMedicineMalignant Blood DisorderImmunologyPharmacology	2010	840
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Matthew S. Davids, Andrew W. Roberts, John F. Seymour, Journal of Clinical Oncology ImmunologyPathologyPharmacotherapyFirst-in-human StudyImmunotherapy	2017	737
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano, Clinical Cancer Research	2016	315
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies Owen A. O’Connor, A. Keith Stewart, Marcy K. Vallone, Clinical Cancer Research	2009	298
The epichaperome is an integrated chaperome network that facilitates tumour survival Anna Rodina, Tai Wang, Pengrong Yan, Nature Tumor BiologyMedicineNatural SciencesPathologyCancer Genomics	2016	293
Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma Craig H. Moskowitz, Matthew J. Matasar, Andrew D. Zelenetz, Blood	2011	280
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom, The Lancet Oncology Lymphoid NeoplasiaRefractory HodgkinAugmented IfosamideBrentuximab VedotinMedicine	2015	263

Page 1